Current State of the First COVID-19 Vaccines
SARS CoV-2 and its associated disease COVID-19 has devastated the world during 2020. Masks and social distancing could be efficient if done by large proportions of the population, but pandemic fatigue has decreased their efficacy. Economic shut downs come with large price tags and cannot be a long t...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/1/30 |
| _version_ | 1797414817468776448 |
|---|---|
| author | Birgit M. Prüβ |
| author_facet | Birgit M. Prüβ |
| author_sort | Birgit M. Prüβ |
| collection | DOAJ |
| description | SARS CoV-2 and its associated disease COVID-19 has devastated the world during 2020. Masks and social distancing could be efficient if done by large proportions of the population, but pandemic fatigue has decreased their efficacy. Economic shut downs come with large price tags and cannot be a long term solution either. The announcements by three vaccine manufacturers in November that their vaccines are 90% or more effective has given hope to at least those in the population who plan to get vaccinated as soon as a scientifically and medically sound vaccine becomes available. This review summarizes the underlying design strategies and current status of development of the nine vaccines that were in phase III trial on 8 November 2020. Contracts between vaccine manufacturing companies and governments aim at distributing the vaccine to a large part of the world population. Questions remain how the temperature sensitive mRNA vaccines will be transported and/or stored and how vaccination will be prioritized within each country. Additionally, current contracts do not cover all countries, with a serious gap in Africa and South America. The second part of this review will detail current distribution plans and remaining challenges with vaccine accessibility and acceptance. |
| first_indexed | 2024-03-09T05:39:27Z |
| format | Article |
| id | doaj.art-b7b5809c219a4313a1ddaf633b6ea63d |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T05:39:27Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-b7b5809c219a4313a1ddaf633b6ea63d2023-12-03T12:26:24ZengMDPI AGVaccines2076-393X2021-01-01913010.3390/vaccines9010030Current State of the First COVID-19 VaccinesBirgit M. Prüβ0Department of Microbiological Sciences, North Dakota State University, Fargo, ND 58104, USASARS CoV-2 and its associated disease COVID-19 has devastated the world during 2020. Masks and social distancing could be efficient if done by large proportions of the population, but pandemic fatigue has decreased their efficacy. Economic shut downs come with large price tags and cannot be a long term solution either. The announcements by three vaccine manufacturers in November that their vaccines are 90% or more effective has given hope to at least those in the population who plan to get vaccinated as soon as a scientifically and medically sound vaccine becomes available. This review summarizes the underlying design strategies and current status of development of the nine vaccines that were in phase III trial on 8 November 2020. Contracts between vaccine manufacturing companies and governments aim at distributing the vaccine to a large part of the world population. Questions remain how the temperature sensitive mRNA vaccines will be transported and/or stored and how vaccination will be prioritized within each country. Additionally, current contracts do not cover all countries, with a serious gap in Africa and South America. The second part of this review will detail current distribution plans and remaining challenges with vaccine accessibility and acceptance.https://www.mdpi.com/2076-393X/9/1/30SARS CoV-2COVID-19vaccine developmentphase III trial |
| spellingShingle | Birgit M. Prüβ Current State of the First COVID-19 Vaccines Vaccines SARS CoV-2 COVID-19 vaccine development phase III trial |
| title | Current State of the First COVID-19 Vaccines |
| title_full | Current State of the First COVID-19 Vaccines |
| title_fullStr | Current State of the First COVID-19 Vaccines |
| title_full_unstemmed | Current State of the First COVID-19 Vaccines |
| title_short | Current State of the First COVID-19 Vaccines |
| title_sort | current state of the first covid 19 vaccines |
| topic | SARS CoV-2 COVID-19 vaccine development phase III trial |
| url | https://www.mdpi.com/2076-393X/9/1/30 |
| work_keys_str_mv | AT birgitmprub currentstateofthefirstcovid19vaccines |